Navigation Links
Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
Date:1/10/2014

Blood (volume 113, number 14), showed that fostamatinib significantly increased the platelet counts of patients including some who had failed currently available TPO agents and may offer a treatment approach that targets the underlying cause of this disease.  Rigel plans to commence a Phase 3 study in this patient population in the first half of the year.

Immunoglobulin A Nephropathy (IgAN) is an autoimmune disease that severely affects the functioning of the kidneys.  An estimated 12,000 Americans are diagnosed with this type of glomerulonephritis each year, with 25% of its victims eventually requiring dialysis and/or kidney transplantation over time. IgAN is characterized by the deposition of IgA immune complexes in the glomeruli of the kidneys leading to an inflammatory response and subsequent tissue damage that ultimately disrupts the normal filtering function of the kidneys. By inhibiting SYK in kidney cells, fostamatinib may block the signaling of IgA immune complex receptors and arrest or slow destruction of the glomeruli. Rigel expects to enter a Phase 2 study of fostamatinib in patients with IgA nephropathy in the spring of 2014.

R348, JAK/SYK Inhibitor for Dry Eye
Approximately 4 million people in the U.S. suffer with dry eye disease, including an estimated 25% of the patients with rheumatoid arthritis and systemic lupus eryathematosus.  Rigel initiated a Phase 2 clinical study to evaluate the safety and potential efficacy of R348, a topical ophthalmic JAK/SYK inhibitor, aimed at reducing the inflammation responsible for the painful symptoms of this disease.  Results of that study are expected in the second half of 2014.

Additionally, according to an article published by the American Academy of Ophthalmology, a significant number (22-80%) of patients with acute or chronic graft vs. host disease (GvHD) develop a secondary incidence of dry eye (keratoconjunctivitis sicca).   I
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel to Present at Oppenheimer Healthcare Conference
2. Rigel Announces Third Quarter 2013 Financial Results
3. Rigel Provides Pipeline Update
4. Rigel to Present at Stifel Healthcare Conference
5. Rigel To Focus On ITP, DLE And Dry Eye
6. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
7. Rigel Announces Second Quarter 2013 Financial Results
8. Rigel Will Resume Responsibility for Fostamatinib Program
9. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
10. Rigel Announces First Quarter 2013 Financial Results
11. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
(Date:8/22/2014)... can be slowed and some of its symptoms ... in pomegranate. Also, the painful inflammation that ... disease could be reduced, according to the findings ... Huddersfield scientist Dr Olumayokun Olajide, who specialises in ... a new phase of research can explore the ...
(Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
(Date:8/22/2014)... The New Jersey Institute for Food, Nutrition ... of New Jersey has joined forces with ChopChop ... young people about health and nutrition in a new ... organizations. , The partnership will encompass quarterly custom editions ... video communications. ChopChop Magazine features plenty of child-friendly ...
(Date:8/22/2014)... very low levels of nicotine may reduce addiction ... a new study from the University of Waterloo. ... Cancer Epidemiology monitored the smoking behaviours ... types of cigarettes with markedly reduced nicotine levels. ... brandsall of which have very similar levels of ...
(Date:8/22/2014)... AcousticSheep LLC participated in one of the largest running ... Run – otherwise known as the “Happiest 5K on the Planet.” ... participants from Erie, surrounding areas, and even from as far away ... largest running events put on in Erie, PA yet – the ... the Planet.” The event took place on August 9, 2014 and ...
Breaking Medicine News(10 mins):Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:RunPhones® Reveals Erie, PA Enthusiasm Impressed Color Run Director 2Health News:RunPhones® Reveals Erie, PA Enthusiasm Impressed Color Run Director 3
... getting action from Cardinal George and Public Official ... ... years ago, health care activist,Joe Novak -- during a private audience with ... of not-for-profit health,care systems, especially those that are Catholic., "Three years ...
... were implemented in poor countries, cases of stunting among under ... up to a quarter, according to new research being published ... Hygiene & Tropical Medicine, is one of the authors of ... and Child Undernutrition Series, which is being launched this week. ...
... 17 Fleishman-Hillard Inc. today pledged,$250,000 in global ... fight to reduce micronutrient deficiencies in developing countries.,Adopting ... Food and,Agribusiness Practice will provide communications strategy and ... of flour standard,practice around the world., One-third ...
... Pill timed to body,s rhythms, helps with morning joint ... A modified-release form of the steroid prednisone is ... joint stiffness in people with rheumatoid arthritis, a new ... Berlin studied 288 people with active rheumatoid arthritis. Half ...
... Texas In the last few years, personalized medicine ... customize treatment for a particular patient has emerged ... , Therapy guided by genetic testing has proven highly ... and lung cancer. Similar personalized therapies are on the ...
... School of Medicine discovered that proteins carrying chemical cargo ... tau protein, which plays an important role in Alzheimers ... cargo towards opposite ends of tracks called microtubules. Tau ... speed bump to regulate protein traffic, the group found. ...
Cached Medicine News:Health News:Ad Campaign Targets Abuses by Not-For-Profits 2Health News:One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented 2Health News:Fleishman-Hillard Names FFI Global Cause for 2008 2Health News:Modified-Release Prednisone May Ease Rheumatoid Arthritis 2Health News:Discovery opens door to 'personalized' asthma therapy 2Health News:Alzheimer's molecule is a smart speed bump on the nerve-cell transport highway 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: